UBS Group’s Precigen PGEN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.44M | Buy |
778,763
+92,679
| +14% | +$401K | ﹤0.01% | 4295 |
|
|
2026
Q1 | $2.66M | Sell |
686,084
-205,344
| -23% | -$843K | ﹤0.01% | 4709 |
|
|
2025
Q4 | $3.73M | Buy |
891,428
+260,824
| +41% | +$1.01M | ﹤0.01% | 4329 |
|
|
2025
Q3 | $2.07M | Buy |
630,604
+274,209
| +77% | +$774K | ﹤0.01% | 4915 |
|
|
2025
Q2 | $506K | Sell |
356,395
-155,912
| -30% | -$222K | ﹤0.01% | 5995 |
|
|
2025
Q1 | $763K | Buy |
512,307
+91,067
| +22% | +$143K | ﹤0.01% | 5514 |
|
|
2024
Q4 | $472K | Buy |
421,240
+321,716
| +323% | +$274K | ﹤0.01% | 5889 |
|
|
2024
Q3 | $94.2K | Buy |
99,524
+10,482
| +12% | +$13.2K | ﹤0.01% | 6417 |
|
|
2024
Q2 | $141K | Sell |
89,042
-80,873
| -48% | -$117K | ﹤0.01% | 5923 |
|
|
2024
Q1 | $246K | Sell |
169,915
-44,641
| -21% | -$64.1K | ﹤0.01% | 5702 |
|
|
2023
Q4 | $288K | Buy |
214,556
+174,835
| +440% | +$205K | ﹤0.01% | 5530 |
|
|
2023
Q3 | $56.4K | Sell |
39,721
-82,324
| -67% | -$117K | ﹤0.01% | 6221 |
|
|
2023
Q2 | $140K | Buy |
122,045
+28,245
| +30% | +$33.3K | ﹤0.01% | 5739 |
|
|
2023
Q1 | $99.4K | Buy |
93,800
+49,883
| +114% | +$71.9K | ﹤0.01% | 5914 |
|
|
2022
Q4 | $66.8K | Sell |
43,917
-3,151
| -7% | -$5.42K | ﹤0.01% | 6490 |
|
|
2022
Q3 | $99K | Buy |
47,068
+11,381
| +32% | +$24K | ﹤0.01% | 5720 |
|
|
2022
Q2 | $48K | Sell |
35,687
-3,776
| -10% | -$5.6K | ﹤0.01% | 5954 |
|
|
2022
Q1 | $83K | Sell |
39,463
-461,356
| -92% | -$1.12M | ﹤0.01% | 6056 |
|
|
2021
Q4 | $1.86M | Buy |
500,819
+215,834
| +76% | +$929K | ﹤0.01% | 3799 |
|
|
2021
Q3 | $1.42M | Buy |
284,985
+171,901
| +152% | +$990K | ﹤0.01% | 3883 |
|
|
2021
Q2 | $738K | Sell |
113,084
-151,385
| -57% | -$1.06M | ﹤0.01% | 4430 |
|
|
2021
Q1 | $1.82M | Buy |
264,469
+151,895
| +135% | +$1.28M | ﹤0.01% | 3650 |
|
|
2020
Q4 | $1.15M | Sell |
112,574
-36,333
| -24% | -$236K | ﹤0.01% | 3895 |
|
|
2020
Q3 | $522K | Buy |
148,907
+14,300
| +11% | +$67.9K | ﹤0.01% | 4157 |
|
|
2020
Q2 | $671K | Buy |
134,607
+7,798
| +6% | +$26.5K | ﹤0.01% | 3890 |
|
|
2020
Q1 | $431K | Sell |
126,809
-8,700
| -6% | -$37.5K | ﹤0.01% | 4101 |
|
|
2019
Q4 | $742K | Sell |
135,509
-16,349
| -11% | -$92K | ﹤0.01% | 4488 |
|
|
2019
Q3 | $869K | Sell |
151,858
-51,302
| -25% | -$349K | ﹤0.01% | 4087 |
|
|
2019
Q2 | $1.56M | Sell |
203,160
-59,801
| -23% | -$322K | ﹤0.01% | 3377 |
|
|
2019
Q1 | $1.38M | Sell |
262,961
-355,976
| -58% | -$2.47M | ﹤0.01% | 3315 |
|
|
2018
Q4 | $4.05M | Buy |
618,937
+386,521
| +166% | +$4.33M | ﹤0.01% | 2347 |
|
|
2018
Q3 | $4M | Buy |
232,416
+78,330
| +51% | +$1.16M | ﹤0.01% | 2561 |
|
|
2018
Q2 | $2.15M | Sell |
154,086
-269,967
| -64% | -$4.56M | ﹤0.01% | 3098 |
|
|
2018
Q1 | $6.5M | Buy |
424,053
+225,905
| +114% | +$3.23M | ﹤0.01% | 2076 |
|
|
2017
Q4 | $2.28M | Buy |
198,148
+50,357
| +34% | +$750K | ﹤0.01% | 3080 |
|
|
2017
Q3 | $2.81M | Buy |
147,791
+18,252
| +14% | +$376K | ﹤0.01% | 2784 |
|
|
2017
Q2 | $3.12M | Buy |
129,539
+2,419
| +2% | +$53K | ﹤0.01% | 2581 |
|
|
2017
Q1 | $2.52M | Sell |
127,120
-193,913
| -60% | -$4.33M | ﹤0.01% | 2725 |
|
|
2016
Q4 | $7.73M | Buy |
321,033
+78,347
| +32% | +$2.18M | ﹤0.01% | 1716 |
|
|
2016
Q3 | $6.74M | Sell |
242,686
-69,383
| -22% | -$1.83M | ﹤0.01% | 1747 |
|
|
2016
Q2 | $7.61M | Buy |
312,069
+179,019
| +135% | +$5.08M | ﹤0.01% | 1588 |
|
|
2016
Q1 | $4.47M | Sell |
133,050
-137,113
| -51% | -$4.32M | ﹤0.01% | 1965 |
|
|
2015
Q4 | $8.07M | Buy |
270,163
+71,850
| +36% | +$2.42M | 0.01% | 1561 |
|
|
2015
Q3 | $6.25M | Buy |
198,313
+85,110
| +75% | +$4.15M | ﹤0.01% | 1731 |
|
|
2015
Q2 | $5.47M | Buy |
113,203
+36,516
| +48% | +$1.54M | ﹤0.01% | 1987 |
|
|
2015
Q1 | $3.33M | Buy |
76,687
+6,949
| +10% | +$250K | ﹤0.01% | 2443 |
|
|
2014
Q4 | $1.83M | Buy |
+69,738
| New | +$1.53M | ﹤0.01% | 2985 |
|
Other funds holding PGEN
PCM
DC
TCM
BCM
IAM
UBS Group's PGEN Position: Q2 2026 in Review
UBS Group increased its Precigen (PGEN) stake by 14% in Q2 2026, buying an estimated $401K and bringing the position to 778,763 shares worth $4.44M. The position accounts for ﹤0.01% of the portfolio, ranked #4295.
UBS Group first reported a position in PGEN in Q4 2014 and has held it in 47 quarters since. The position peaked at $8.07M in Q4 2015. 211 funds tracked by Wall St. Rank hold PGEN as of Q2 2026.
- UBS Group held 778,763 shares of Precigen worth $4.44M as of Q2 2026.
- UBS Group bought 92,679 Precigen shares in Q2 2026, an estimated $401K.
- Precigen made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4295 holding.
- UBS Group first reported a position in Precigen in Q4 2014 and has held it in 47 quarters since.
- UBS Group's Precigen position peaked at $8.07M in Q4 2015.
- 211 funds tracked by Wall St. Rank held Precigen as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.